A 12-month multicenter, randomized phase III study comparing a 13.5 mg levonorgestrel intrauterine contraceptive system with the etonogestrel subdermal contraceptive implant in women aged 18–35 years

Abstract

To compare 12-month rates of discontinuation (primary outcome), user satisfaction and adverse events (AEs) (secondary outcomes) associated with the use of a new 13.5 mg (total content) levonorgestrel intrauterine contraceptive system (LNG-IUS 13.5 mg; Jaydess®) and the etonogestrel subdermal contraceptive implant (ENG implant, Nexplanon®).